Unilateral vs bilateral hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases: A randomized single-blind phase 2 clinical trial
Neuro-Oncology · 16.10.2026
DOI: 10.1093/neuonc/noag261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 16.10.2026. Verfasst von Wen-Chi Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Taiwan University Hospital.
Abstract (Originalsprache)
Background
Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) with memantine reduces, but does not eliminate, cognitive decline. Left hippocampal dose may be more closely associated with cognitive outcomes. We investigated whether unilateral (left) HA-WBRT is equivalent to bilateral HA-WBRT for neurocognitive function.
Methods
In this randomized, single-blind, phase 2 equivalence trial, patients with brain metastases were assigned 1:1 to unilateral (left) or bilateral HA-WBRT (30 Gy in 10 fractions) with concurrent memantine. The primary endpoint was relative decline in Hopkins Verbal Learning Test-Revised (HVLT-R) memory score from baseline to 6 months; equivalence required the 90% CI for the between-arm difference to fall within ±15 percentage points.
Results
Among 73 patients (unilateral, n = 36; bilateral, n = 37; median follow-up, 13.2 months), mean 6-month relative HVLT-R decline was 4.75% versus 5.05% (difference, −0.31 percentage points; 90% CI, −12.02 to 11.40 percentage points; TOST P = .02), meeting the equivalence criterion. Brain progression-free survival (10.3 vs 10.8 months; P = .96), overall survival (17.8 vs 12.8 months; P = .94), acute toxicity (≥grade 2, 44.4% vs 35.1%; P = .43), and 6-month neurocognitive failure (61.1% vs 56.8%; Gray test P = .78) were similar. Global health status appeared more stable with unilateral HA-WBRT (interaction, P < .001). Exploratory plasma brain-derived neurotrophic factor (BDNF) trajectories varied by neurocognitive failure status (FDR q = .09).
Conclusions
Unilateral (left) HA-WBRT with memantine met the prespecified equivalence criterion for verbal memory, with comparable oncologic outcomes and safety; non-verbal memory was not assessed. These findings warrant validation, particularly when bilateral avoidance is challenging.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
- Division of Radiation Oncology, Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Psychology, National Chengchi University, Taipei, Taiwan.
- Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
Förderung
- National Taiwan University Hospital
Zitieren
APA
Yang, W. C., Chen, Y. F., Yang, C. C., Lu, S. H., Lu, S. L., Kuo, M. C., Chang, C. H., & Hsu, F. M. (2026). Unilateral vs bilateral hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases: A randomized single-blind phase 2 clinical trial. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag261
Vancouver
Yang WC, Chen YF, Yang CC, Lu SH, Lu SL, Kuo MC, et al. Unilateral vs bilateral hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases: A randomized single-blind phase 2 clinical trial. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag261
BibTeX
@article{Yang2026,
author = {Yang, Wen-Chi and Chen, Ya-Fang and Yang, Chi-Cheng and Lu, Szu-Huai and Lu, Shao-Lun and Kuo, Ming-Che and Chang, Chin-Hao and Hsu, Feng-Ming},
title = {Unilateral vs bilateral hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases: A randomized single-blind phase 2 clinical trial},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag261}
}
EUVIMED